https://news.longevitytrader.com/ 2026-05-01 https://news.longevitytrader.com/about-us 2026-05-01 https://news.longevitytrader.com/archive 2026-04-30 https://news.longevitytrader.com/methodology 2026-04-30 https://news.longevitytrader.com/subscribe 2026-04-30 https://news.longevitytrader.com/authors 2026-05-05 https://news.longevitytrader.com/p/the-breakthrough-is-here-but-the-market-hasn-t-caught-up 2026-05-04 Longevity Trader en 2026-05-04T19:41:45Z The Breakthrough Is Here—But the Market Hasn’t Caught Up https://news.longevitytrader.com/p/the-1000x-sentinel-4-overlooked-biotech-companies-with-asymmetric-upside 2026-04-30 https://news.longevitytrader.com/p/major-breakthroughs-in-regenerative-medicine-favor-these-overlooked-companies 2026-04-30 https://news.longevitytrader.com/p/the-100b-drug-creating-a-new-market-no-one-is-pricing-in 2026-04-30 https://news.longevitytrader.com/p/the-aesthetics-boom-and-why-temporary-fixes-won-t-be-enough 2026-04-30 https://news.longevitytrader.com/p/the-hidden-layer-of-biotech-that-could-produce-the-biggest-winners 2026-04-30 https://news.longevitytrader.com/p/this-regenerative-medicine-company-looks-ipo-ready-here-s-what-to-watch 2026-04-30